Cargando…

A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy

INTRODUCTION: Poor cell uptake and incomplete intracellular drug release are the two major challenges for polymeric prodrug-based drug delivery systems (PPDDSs) in cancer treatment. METHODS: Herein, a PPDDS with pH-induced surface charge-reversal and reactive oxygen species (ROS) amplification for R...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chen, Song, Rijin, Lu, Pei, Chen, Jianchun, Zhou, Yongqiang, Shen, Gang, Jiang, Minjun, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955620/
https://www.ncbi.nlm.nih.gov/pubmed/32021165
http://dx.doi.org/10.2147/IJN.S230237
_version_ 1783486970801946624
author Xu, Chen
Song, Rijin
Lu, Pei
Chen, Jianchun
Zhou, Yongqiang
Shen, Gang
Jiang, Minjun
Zhang, Wei
author_facet Xu, Chen
Song, Rijin
Lu, Pei
Chen, Jianchun
Zhou, Yongqiang
Shen, Gang
Jiang, Minjun
Zhang, Wei
author_sort Xu, Chen
collection PubMed
description INTRODUCTION: Poor cell uptake and incomplete intracellular drug release are the two major challenges for polymeric prodrug-based drug delivery systems (PPDDSs) in cancer treatment. METHODS: Herein, a PPDDS with pH-induced surface charge-reversal and reactive oxygen species (ROS) amplification for ROS-triggered self-accelerating drug release was developed, which was formed by encapsulating a ROS generation agent (vitamin K3 (VK3)) in pH/ROS dual-sensitive polymetric prodrug (PEG-b-P(LL-g-TK-PTX)-(LL-g-DMA)) based micelle nanoparticles (denoted as PVD-NPs). RESULTS: The surface charge of the PVD-NPs can change from negative to positive for enhanced cell uptake in response to tumor extracellular acidity pH. After internalization by cancer cells, PVD-NPs demonstrate dual drug release in response to intracellular ROS-rich conditions. In addition, the released VK3 can produce ROS under the catalysis by NAD(P)H:quinone oxidoreductase-1, which facilitates tumor-specific ROS amplification and drug release selectively in cancer cells to enhance chemotherapy. CONCLUSION: Both in vitro and in vivo experiments demonstrated that the PVD-NPs showed significant antitumor activity in human prostate cancer.
format Online
Article
Text
id pubmed-6955620
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69556202020-02-04 A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy Xu, Chen Song, Rijin Lu, Pei Chen, Jianchun Zhou, Yongqiang Shen, Gang Jiang, Minjun Zhang, Wei Int J Nanomedicine Original Research INTRODUCTION: Poor cell uptake and incomplete intracellular drug release are the two major challenges for polymeric prodrug-based drug delivery systems (PPDDSs) in cancer treatment. METHODS: Herein, a PPDDS with pH-induced surface charge-reversal and reactive oxygen species (ROS) amplification for ROS-triggered self-accelerating drug release was developed, which was formed by encapsulating a ROS generation agent (vitamin K3 (VK3)) in pH/ROS dual-sensitive polymetric prodrug (PEG-b-P(LL-g-TK-PTX)-(LL-g-DMA)) based micelle nanoparticles (denoted as PVD-NPs). RESULTS: The surface charge of the PVD-NPs can change from negative to positive for enhanced cell uptake in response to tumor extracellular acidity pH. After internalization by cancer cells, PVD-NPs demonstrate dual drug release in response to intracellular ROS-rich conditions. In addition, the released VK3 can produce ROS under the catalysis by NAD(P)H:quinone oxidoreductase-1, which facilitates tumor-specific ROS amplification and drug release selectively in cancer cells to enhance chemotherapy. CONCLUSION: Both in vitro and in vivo experiments demonstrated that the PVD-NPs showed significant antitumor activity in human prostate cancer. Dove 2020-01-08 /pmc/articles/PMC6955620/ /pubmed/32021165 http://dx.doi.org/10.2147/IJN.S230237 Text en © 2020 Xu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Xu, Chen
Song, Rijin
Lu, Pei
Chen, Jianchun
Zhou, Yongqiang
Shen, Gang
Jiang, Minjun
Zhang, Wei
A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy
title A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy
title_full A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy
title_fullStr A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy
title_full_unstemmed A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy
title_short A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy
title_sort ph-responsive charge-reversal drug delivery system with tumor-specific drug release and ros generation for cancer therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955620/
https://www.ncbi.nlm.nih.gov/pubmed/32021165
http://dx.doi.org/10.2147/IJN.S230237
work_keys_str_mv AT xuchen aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT songrijin aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT lupei aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT chenjianchun aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT zhouyongqiang aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT shengang aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT jiangminjun aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT zhangwei aphresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT xuchen phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT songrijin phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT lupei phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT chenjianchun phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT zhouyongqiang phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT shengang phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT jiangminjun phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy
AT zhangwei phresponsivechargereversaldrugdeliverysystemwithtumorspecificdrugreleaseandrosgenerationforcancertherapy